691TiP PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation
Year: 2024
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Authors: A.M. Schram, G. Lopes, A.B. El-Khoueiry, E. Fontana, T.B. Karasic, S. Kummar, P. Lorusso, V. Gregorc, M. Millward, S. Ponce Aix, D.L. Richardson, D. Roda Perez, A.I. Spira, D.S. Tan, J.A. Thompson, D. Uprety, M. Fellous, Y.G. Qin, E.E. Dumbrava
Institutions: Memorial Sloan Kettering Cancer Center, Sylvester Comprehensive Cancer Center, University of Southern California, USC Norris Comprehensive Cancer Center, Sarah Cannon Research Institute, Abramson Cancer Center, University of Pennsylvania, Oregon Health & Science University, OHSU Knight Cancer Institute, Yale Cancer Center, Yale University, Linear Clinical Research, Institut Gustave Roussy, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Hospital Clínico Universitario de Valencia, Virginia Cancer Specialists, National University of Singapore, National University Cancer Institute, Singapore, National University Hospital, Fred Hutch Cancer Center, The Barbara Ann Karmanos Cancer Institute, PMV Pharmaceuticals, Inc. (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4402558623